Replies to post #339645 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

A prescription drug; and for sleep.

It will be quite a while before 2-73 becomes over the counter or available at that low price.

None of the Anavex drugs may ever be sold over the counter. At wrong, too-high dosages probably untoward side effects.

Nonetheless, it may well become a commonly prescribed drug, treating many millions.

Consider the early clinical results that indicate that, among other benefits, blarcamesine produces sound, healthful sleep. Perhaps it will not prove to be an anti-aging drug. But, what if it produces sound, healthful sleep, without side effects? Would physicians have any impulse to then prescribe the drug as a chronic (long-term) soporific? Is poor sleep a major health problem? It surely is; presently lacking good solutions. A few current drugs do induce sleep, but have a host of untoward side effects; many of which are worse than the sleeplessness the drug is putatively treating.

Poor sleep patterns complicate or produce a wide diversity of other diseases and conditions. Poor sleep, it is thought, increases the probability of Alzheimer’s.

So, an Anavex soporific may well become a widely-prescribed new drug for sleep problems. Let’s see if improved sleep is recorded and reported in any of the three on-going clinical trials of blarcamesine.

The market for successfully obviating insomnia in the U.S. is gigantic:
“Estimates of total insomnia-related costs in the United States have ranged from $30 to $35 billion per year to $92.5 to $107.5 billion per year. These costs include direct treatment costs, such as physician encounters and prescriptions, as well as indirect costs, such as consumption of medical services, increased accident risk, and lost workplace productivity.”
https://sleepreviewmag.com/uncategorized/financial-costs-insomnia/